Bone Biologics Corp
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
BBLG$0.33-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| (a) | Exhibits required by Item 601 of Regulation S-K. |
| Exhibit · Incorporated by reference (unless otherwise indicated) | |||||
|---|---|---|---|---|---|
| Number | Exhibit Title | Form | File | Exhibit | Filing date |
| 4.1 | Form of New Warrant dated August 2, 2024. | Form 8-K | 001-40899 | 4.1 | August 2, 2024 |
| 4.2 | Form of Placement Agent Warrant dated August 2, 2024. | Form 8-K | 001-40899 | 4.2 | August 2, 2024 |
| 10.1 | Form of Inducement Letter Agreement dated August 1, 2024. | Form 8-K | 001-40899 | 10.1 | August 2, 2024 |
| 10.2 | At The Market Offering Agreement, dated September 27, 2024, by and between Bone Biologics Corporation and H.C. Wainwright & Co., LLC | Form 8-K | 001-40899 | 1.1 | September 27, 2024 |
| 31.1* | Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Report on Form 10-Q for the quarter ended September 30, 2024. | — | — | — | — |
| 31.2* | Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Report on Form 10-Q for the quarter ended September 30, 2024. | — | — | — | — |
| 32.1* | Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | — | — | — | — |
| 32.2* | Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | — | — | — | — |
| 101.INS* | Inline XBRL Instance Document | — | — | — | — |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | — | — | — | — |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | — | — | — | — |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | — | — | — | — |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | — | — | — | — |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | — | — | — | — |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
- Filed Herewith
- Management contract or compensatory arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.